Join
Live feed
·
INSIDERFilingvia Quantisnow
AN2 Therapeutics Inc. logo

Chief Development Officer Chanda Sanjay was granted 50,250 shares, increasing direct ownership by 168% to 80,074 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ANTX· AN2 Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANTX (AN2 Therapeutics Inc.) and more on Quantisnow.